icon-folder.gif   Conference Reports for NATAP  
  Paris Special EASL Meeting
Pais, France
September 23-24, 2016
Back grey_arrow_rt.gif
Analysis of Baseline Variants in GT1a-Infected Pati ents Treated With 3D With and Without RBV, and Cirrhotic GT1a Patients Treated With 3D Plus RBV for 12 or 24 Weeks
  Reported by Jules Levin
EASL/ASSLD- New Perspectives in Hepatitis C Virus Infection-The Roadmap for Cure, 23-24 September 2016, Paris, France
Christoph Sarrazin1, Mark S Sulkowski2, Preethi Krishnan3, Rakesh Tripathi3, Gretja Schnell3, Daniel E Cohen3, Roger Trinh3, Lino Rodrigues-Jr3,
Yan Luo3, Nancy S Shulman3, Tami Pilot-Mati as3, Christi ne Collins3
1JW Goethe University Hospital, Frankfurt, Germany; 2Viral Hepati ti s Center, Johns Hopkins University, Balti more, Maryland, United States; 3AbbVie Inc., North Chicago, Illinois, United States











1. Dvory-Sobol, et al. (2014) The Prevalence of HCV NS5A, Nucleoside and Protease Inhibitor Resistance Associated Variants and the Eff ects on Treatment with Ledipasvir/Sofosbuvir RBV in the Phase 3 ION Studies. Internati onal Workshop on Anti viral Drug Resistance. Berlin, Germany.
Sarrazin, et al. (2015) The Prevalence and the Eff ect of HCV NS5A Resistance-Associated Variants in Pati ents with Compensated Cirrhosis Treated with Ledipasvir/Sofosbuvir RBV. EASL, Vienna, Austria.
Zepati er, 2016 US prescribing informati on.
2. Krishnan, et al. (2014) Pooled Analysis of Resistance in Pati ents Treated with Ombitasvir/ABT-450/r and Dasabuvir with or without Ribavirin in Phase 2 and Phase 3 Clinical Trials. AASLD, Boston, MA. Krishnan, et al. (2015) Long-term Follow-up of Treatment-emergent Variants in NS3, NS5A and NS5B with Paritaprevir/r-, Ombitasvir- and Dasabuvir-based Regimens. EASL, Vienna, Austria.
3. Sulkowski, et al. (2016) Eff ect of baseline resistance-associated variants on SVR with the 3D regimen plus RBV. CROI, Boston, MA.
4. Sarrazin, et al. (2016) Eff ect of baseline resistance-associated variants on SVR with the 3D regimen plus RBV. EASL, Barcelona, Spain.
5. Firenci, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014 May 22;370(21):1983-92.